ORAL LICHEN PLANUS IS A
|
|
- Curtis Owens
- 5 years ago
- Views:
Transcription
1 Recalcitrant Symptomatic Vulvar Lichen Planus Response to Topical Tacrolimus OBSERVATION Julie A. Byrd, MD; Mark D. P. Davis, MD; Roy S. Rogers III, MD Background: Topical tacrolimus has been reported to be an effective treatment for genital lichen planus in small case series. We retrospectively reviewed the medical records of 16 patients with symptomatic vulvar lichen planus who received treatment with tacrolimus ointment. Observations: All patients had symptomatic vulvar lichen planus recalcitrant to other treatments. Of 16 patients, 15 (94%) experienced a symptomatic response to tacrolimus treatment within 3 months (mean, 4.2 weeks) and had a partial or complete resolution of the lesions. Six patients (38%) reported mild adverse effects, irritation, burning, and tingling. With continued use of the medication, these adverse effects resolved. When patients stopped treatment, lichen planus returned in 10 (83%) of 12 patients within 6 months after discontinuation of therapy (median, 1 week; range, weeks), but in 6 patients the lesions were less severe than the lesions before treatment; all 10 patients resumed use of topical tacrolimus. Conclusions: In this retrospective series of 16 women with vulvar lichen planus, topical tacrolimus therapy effectively controlled symptoms and improved lesions in all but 1 patient. The effect may be temporary, requiring continued use of tacrolimus, which appears to be safe and effective in controlling disease activity. Arch Dermatol. 2004;140: From the Department of Dermatology, Mayo Clinic, Rochester, Minn. The authors have no relevant financial interest in this article. ORAL LICHEN PLANUS IS A relatively common condition affecting approximately 1% of the population. 1-4 Lichen planus is more common in women, and in 1 study it involved the genitalia in 25% of the women with oral lichen planus. 5 Genital lichen planus causes considerable discomfort, which may be debilitating. Typically, patients present in their fifth or sixth decade with pruritus, burning, pain, and dyspareunia. Physical examination findings range from erythema to erosions and frank ulcerations; in severe disease, vaginal adhesions and scarring develop, prohibiting sexual intercourse. 6-9 Besides the mouth and genitalia, other mucosal sites that may be involved with lichen planus include the esophagus, conjunctiva, and ear canals. Lichen planus in these sites may lead to scarring, resulting in disability and morbidity. 10 Scarring usually does not occur with oral lichen planus. Histopathologic examination reveals a lichenoid infiltrate, basal layer vacuolation, and scattered Civatte bodies. As expected, at mucosal sites many plasma cells may also be present. Direct immunofluorescence studies consistent with lichen planus and other lichenoid reactions reveal shaggy fibrinogen deposition at the dermalepidermal junction, with cytoid bodies staining with 1 or more of the following conjugates: IgG, IgM, IgA, or C3. 11,12 Therapeutic management is challenging. Genital lichen planus may be more severe and recalcitrant to treatment compared with oral lichen planus. 9,10 Variable benefit occurs with use of topical agents, such as antifungal agents, retinoids, estrogens, and cyclosporine, as well as systemic agents, such as retinoids, antifungal agents, hydroxychloroquine, and dapsone. 10,21-28 Frequently, systemic treatments have unproven benefit, expose the patient to adverse effects, and are expensive. Topical tacrolimus is an effective and safe therapy for oral lichen planus This therapy has been used for other mucosal forms of lichen planus, and there are reports of its efficacy for genital lichen planus. 29,35 We prescribed topical tacrolimus for 16 consecutive patients with symptomatic vulvar lichen planus; we report their responses to treatment in this study. 715
2 1. For how many weeks or months did you use tacrolimus ointment before you saw improvement? 2. When using tacrolimus ointment, how much better were the symptoms of lichen planus? Much Better 3. When using tacrolimus ointment, how much did the lesions change? Completely Gone Somewhat Better Weeks or Almost Gone If "Yes," what were the problems? 5. Are you currently using tacrolimus ointment? If "Yes," how often do you use tacrolimus ointment? Why did you stop using tacrolimus ointment? After you stopped using tacrolimus ointment, did your lichen planus stay the same or come back? When it came back, was it: Weeks or Months About the Same 6. Overall, how satisfied are you with tacrolimus ointment? METHODS The Same Somewhat Worse 4. Did you have any problems with tacrolimus ointment? No Yes Irritation Burning Tingling Other Months Much Worse Increased Twice Daily Once Daily 3 Times Weekly Weekly If "No," when did you stop using tacrolimus ointment? (month/day/year) Side Effects Stayed the Same Very Satisfied Worse Than Before Cost of the Medication Neither Satisfied nor Dissatisfied Somewhat Dissatisfied Came Back The Same as Before Somewhat Satisfied No Change in Lichen Planus If it came back, how long after stopping use of tacrolimus ointment did it come back? Very Dissatisfied Much Better Than Before Other Patient telephone questionnaire for follow-up of patients who were using tacrolimus ointment (Protopic; Fujisawa Healthcare, Inc, Deerfield, Ill). We retrospectively reviewed the medical records of 16 consecutive female patients with symptomatic vulvar lichen planus who were treated with topical tacrolimus. All patients were evaluated and treated in the Department of Dermatology at Mayo Clinic in Rochester, Minn, by the same clinician (R.S.R.) between April 2000 and November Patients fulfilled the following criteria: (1) vulvar lichen planus was diagnosed on the basis of history, physical examination, and, if available, histopathologic features of lichenoid mucositis with or without supportive direct immunofluorescence studies and (2) patients received treatment with topical tacrolimus for vulvar lichen planus. Topical tacrolimus 0.1% ointment (Protopic; Fujisawa Healthcare, Inc, Deerfield, Ill) was prescribed for all patients. They were instructed to apply the ointment to affected areas twice daily. Before this product was available, 8 patients initially used topical tacrolimus prepared by the Mayo Clinic pharmacy: tacrolimus capsules (Prograf; Fujisawa) were compounded in a bland ointment base (Aquaphor; Beiersdorf, South Norwalk, Conn) in 2 concentrations, 0.1% (3 patients) and 0.03% (5 patients), until the commercial form became available. Neither the physician nor the patient perceived a difference between the Protopic ointment and the compounded product. Follow-up data were obtained by means of a patient telephone questionnaire. The use of this questionnaire was approved by the Mayo Foundation Institutional Review Board. The topics of the questions included symptoms and lesions, use of the ointment, and patient satisfaction (Figure). Response to treatment was evaluated according to change in symptoms and clearance of lesions. Symptoms were graded on the following scale: much better, somewhat better, about the same, somewhat worse, or much worse. Patients who responded that their symptoms were much better or somewhat better were considered to have had a symptomatic response. Patients were asked whether the lesions were completely gone, almost gone, the same, or increased after treatment. Lesions were considered completely resolved if the patient believed that the lesions were completely gone; lesions were considered partially resolved if the patient believed that the lesions were almost gone. In addition to the patient questionnaire, a retrospective review of the patients medical charts was performed to obtain clinical examination findings after the use of topical tacrolimus. If use of the medication was discontinued, the patient was asked whether the disease relapsed, when the relapse occurred, and how the severity of the relapse compared with the episode before treatment (worse than before, the same as before, or much better than before). Patient satisfaction with the use of tacrolimus was determined (very satisfied, somewhat satisfied, neither satisfied nor dissatisfied, somewhat dissatisfied, or very dissatisfied). RESULTS Demographic and clinical data from the patients studied are summarized in Table 1. All 16 patients were white women. Age ranged from 47 to 75 years (mean, 63 years). All patients had painful, erosive lesions of vulvar lichen planus. Reported symptoms included pain in 16 patients, soreness in 4, burning in 3, and bleeding in 1. The diagnosis of lichen planus was confirmed with biopsy results in 12 (75%) of the 16 patients. Of these 12 patients, 5 had direct immunofluorescence findings that showed changes consistent with lichen planus. One patient had nondiagnostic findings on direct immunofluorescence testing. Clinical diagnosis in others was made on the basis of the presence of concomitant oral,, otic, or esophageal lichen planus. The was involved in 14 patients, and the vulva in 6. Labial involvement was present in 6 patients; in 2 of these patients the inflammation and destruction from lichen planus had obliterated the labia minora and majora. Lichen planus involved extragenital sites in most of these patients (Table 1): oral mucosa in 14 patients, skin in 5, ear in 3, esophagus in 2, and the perianal region in 2. The mean duration of disease before initiation of therapy with topical tacrolimus was 4.3 years (range, 1-12 years). All patients had recalcitrant disease, and all patients had tried at least 1 form of treatment before receiving tacrolimus therapy. Prior treatments included use of topical corticosteroids (13 patients), antifungal medications (7 patients), topical estrogen (5 patients), systemic corticosteroids (5 patients), and hydroxychloro- 716
3 Table 1. Data for Patients Using Topical Tacrolimus for Vulvar Lichen Planus Patient No./ Age, y/ Duration, y Site Symptoms in Genital Area Signs of Vulvar Lichen Planus Extragenital Involvement Biopsy Specimen DIF Results Prior Treatment 1/75/10 Introitus Pain, bleeding Erosions None Not done Topical corticosteroids 2/69/1 Vulva Pain Erosions, scarring Oral None Not done Topical oral corticosteroid 3/74/4 Vulva, Pain, soreness Erosions None Vulva Not done Topical antifungal 4/72/1 Introitus Pain, soreness Erosions Gingival, Nondiagnostic results Not done Topical topical estrogen 5/60/6 Vulva, labia Pain Erosions, scarring otic Gingiva and vulva Positive Topical hydroxychloroquine, oral corticosteroid 6/47/4 Introitus Pain Erosions Gingival Gingiva Positive Topical antifungal, hydroxychloroquine, topical estrogen 7/57/2 Vulva, Pain Erosions perianal Gingiva and labia Positive Topical antifungal 8/47/2 Introitus Pain Erosions Oral, gingival Vagina Not done Antifungal, hydroxychloroquine 9/53/6 Introitus, labia Pain Erosions, stenosis otic Vagina Not done Topical antifungal 10/74/6 Vulva, Pain, soreness Erosions Gingival, Gingiva Positive Topical corticosteroids perianal 11/66/5 Introitus, labia Pain, burning Erosions Gingival, Wrist Not done Oral corticosteroid 12/49/1 Introitus, labia Pain Erosions, scarring esophageal None Not done Topical antifungal, oral corticosteroid, hydroxychloroquine* 13/68/3 Introitus Pain, burning Erosions None Vulva Positive Topical antifungal, topical estrogen, oral corticosteroid* 14/65/12 Vulva, 15/67/4 Introitus, labia Pain, soreness, burning Pain Erosions Oral, gingival Labia majora Not done Topical retinoid Erosions, stenosis, labia destroyed 16/67/1 Introitus, labia Pain Erosions, stenosis, labia destroyed Abbreviation: DIF, direct immunofluorescence. *Patient used this medication concomitantly with topical tacrolimus., otic, esophageal Vulva Not done Topical topical estrogen Esophageal Nondiagnostic Topical estrogen quine (4 patients). Two patients continued to receive systemic therapy during topical tacrolimus therapy: 1 received oral corticosteroids and the other received hydroxychloroquine. Both patients were able to decrease the dose of systemic medication when topical tacrolimus therapy was initiated. A summary of the responses of the patients to initiation of therapy with topical tacrolimus is presented in Table 2. Of the 16 patients, 15 (94%) experienced a symptomatic response to treatment within 3 months (mean, 4.2 weeks; range, weeks). These 15 patients also noted partial or complete resolution of the vulvar lesions. One had no symptomatic improvement. Patients were followed up for at least 2 months (mean, 15.7 months; range, 2-28 months). Clinical examination findings are available in Table 2. Of the 16 patients, 13 returned for follow-up appointments. Of these 13, 10 had no clinical evidence of erosions and 3 had smaller erosions that were healing. Follow-up examination occurred in an average of 3 months (range, 1-12 months) after initiation of topical tacrolimus therapy. Twelve patients stopped applying topical tacrolimus for various reasons (Table 3): 7 stopped because the lichen planus resolved, 3 forgot to apply it, 1 stopped because of adverse effects (burning and irritation), and 717
4 Table 2. Response to Topical Tacrolimus Therapy* Patient No. Time Before Response, wk Change in Symptoms Change in Lesion Adverse Effects Objective Findings on Follow-up Examination (Months of Therapy) Frequency of Current Use Follow-up Duration, mo 1 3 Somewhat better Almost gone Itching No erosions; erythema present (12) Weekly Much better Completely gone None No erosions or erythema (4) Once daily 14 3 NA None None None NA None Much better Almost gone None No erosions; erythema present (3) 3 times/wk Somewhat better Almost gone Burning, irritation Erosions healing (1) Weekly Somewhat better Almost gone None Erosions healing (2) Twice daily Much better Almost gone Burning No erosions or erythema (3) Once daily Much better Completely gone None NA Once daily Much better Almost gone Burning No erosions or erythema (1) Once daily Much better Completely gone Burning NA Weekly Much better Almost gone None No erosions; erythema present (7) Weekly Much better Almost gone None No erosions or erythema (1) Twice daily Much better Almost gone None No erosions or erythema (1.5) Once daily Much better Almost gone Tingling Erosions healing (6) None Much better Almost gone None No erosions; erythema present (2) Once daily Much better Completely gone None No erosions or erythema (1) Once daily 9 Abbreviation: NA, not applicable. *Frequency of initial application was twice daily for all patients. Table 3. Recurrence of Lichen Planus in Patients Who Discontinued Use of Topical Tacrolimus* Patient No. Reason for Stopping Therapy Time Before Recurrence, wk Severity of Lesion at Recurrence Compared With Before Therapy 1 LP resolved 3 Worse 2 LP resolved 2 Much better 3 No change in LP NA NA 4 LP resolved 0.3 Much better 5 Adverse effects 3 Same 6 Forgot to apply 1 Same 7 Forgot to apply 0.3 Much better 8 NA NA NA 9 NA NA NA 10 LP resolved 1 Same 11 LP resolved 24 Much better 12 NA NA NA 13 LP resolved 1 Much better 14 LP resolved NA NA 15 Forgot to apply 1 Much better 16 NA NA NA Abbreviations: LP, lichen planus; NA, not applicable. *Lichen planus recurred in all these patients except patient believed that the medicine was not helping. In 10 patients the lesions recurred within 6 months after discontinuation of therapy with topical tacrolimus (median, 1 week; range, weeks). The recurrent lesions, compared with lesions before therapy, were less severe or of the same severity in 9 patients. One patient believed that her lesions recurred in a more severe form, and 1 patient believed that her lesions were unchanged during topical tacrolimus therapy (therefore, stopping the therapy did not result in any change in her lesions). Remission of lichen planus occurred in 1 patient (duration of followup, 25 months). Minor adverse effects occurred in 6 patients, irritation, burning, and tingling. One patient discontinued using topical tacrolimus because of adverse effects, but when the lesions recurred, she reapplied it and had no adverse effects. The patients who experienced adverse effects stated that they resolved with continued use of tacrolimus. At present, 14 patients continue to use topical tacrolimus: 2 apply it twice daily, 7 apply it once daily, 1 applies it 3 times weekly, and 4 apply it weekly. Fifteen patients reported satisfaction with the treatment. COMMENT Topical tacrolimus ointment was remarkably effective in controlling the symptoms of recalcitrant vulvar lichen planus in all but 1 of the patients studied. Of the 16 female patients, 15 (94%) reported that their symptoms and lesions had improved. However, in most patients the benefit was not sustained. Soon after the patients stopped the treatment, the lesions and symptoms returned; in most patients, however, the lesions were less severe than the lesions before treatment, and the lesions responded when topical therapy was resumed. The tacrolimus was well tolerated; symptoms of burning resolved with continued use of the ointment. Our results are consistent with results from previous reports of recalcitrant genital lichen planus that responded to topical tacrolimus (Table 4). However, we report a larger number of patients than that previously reported, and we describe a relatively long duration of follow-up (mean, 15.7 months). We believe that our results are valid: the diagnosis of lichen planus was made in a consistent manner (diagnosed by 1 physician; confirmed in more than two thirds of the cases with oral, vulvar, or esophageal biopsy); the treatment was consistently prescribed and advised; and follow-up data were obtained by 1 physician in a consistent, standardized manner. All but 2 of the patients with vulvar lichen planus had lichen planus at multiple sites. These patients had oral,, otic, esophageal, perianal, or perineal lichen planus in addition to genital in- 718
5 Table 4. Previously Reported Cases of Genital Lichen Planus Responding to Therapy With Topical Tacrolimus* Vente et al 29 Kirtschig et al 35 Characteristic Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Age, y Duration of disease, y Genital site Vulva, Vulva, Vulva, Vulva, vagina Vulva, vagina Extragenital involvement Oral None None Oral Oral Prior treatment Topical topical retinoids Topical antimycotics, estrogen Topical topical retinoids, topical cyclosporine Topical and oral dapsone, griseofulvin, acitretin, hydroxychloroquine Topical and oral dapsone, griseofulvin, acitretin, hydroxychloroquine Frequency of application Twice daily Twice daily Twice daily 3 Times weekly 3 times weekly Time to response 4 wk to complete resolution 4 wk to good improvement; 8 wk to further improvement 4 wk to little improvement; 16 wk to almost complete resolution 4 wk to improvement; 8 wk to completely healed 4 wk to improvement; 12 wk to controlled Current use Unknown Unknown Unknown Once weekly 3 times weekly Occurrence of relapse after 3 wk No relapse 6 mo 3 wk Unknown Unknown cessation of therapy after cessation Adverse effects Slight burning None None Slight burning Slight burning Duration of follow-up, wk *All patients were women. Patients received 0.1% tacrolimus (Prograf; Fujisawa Healthcare, Inc, Deerfield, Ill) in a hydrophilic petrolatum ointment containing bleached beeswax, stearyl alcohol, cholesterol, and white petrolatum. Patients received 0.1% tacrolimus (Prograf; Fujisawa) in a paraffin ointment. volvement. Many of the patients had the vulvovaginalgingival variant of erosive lichen planus, which has been reported to be more recalcitrant to treatment. All patients had not had a response with other treatments. We recognize that a retrospective review of clinical material is not optimal; however, we benefited from the consistency of 1 expert physician making the diagnosis. Follow-up data were obtained by means of a telephone survey, which has its own shortcomings because the patients are subject to recall bias and memory lapses. However, we tried to avoid creating bias in our telephone survey. The survey was the only practical means of following up our patients because many of them lived too far from our institution to conveniently return for follow-up. Yet the patients who returned for follow-up had improvement on clinical examination that was consistent with the questionnaire responses. Genital lichen planus is well recognized as a debilitating condition for many patients. Symptoms of genital pruritus, burning, pain, and dyspareunia may have detrimental psychological effects. Erosions and ulcerations due to lichen planus may lead to scarring and adhesions that prohibit sexual intercourse. Treatment options are limited by the lack of consistently effective and safe drugs. Surgical procedures to reconstruct the stenotic, fibrosed vaginal vault have been performed; however, scarring frequently recurs after the procedure. 10 Tacrolimus is a macrolide immune modulator produced by Streptomyces tsukubaensis, which has been reported to be effective in treating oral lichen planus Tacrolimus has also been reported to be effective for treatment of erosive vulvovaginal lichen planus. 29,35 Although the exact mechanism of action in treating lichen planus is unknown, topical tacrolimus has been shown to inhibit T-lymphocyte activation by inhibiting the phosphatase activity of calcineurin. Without calcineurin to dephosphorylate the nuclear factor of activated T cells, gene transcription for lymphokines, interleukin 2, and -interferon is inhibited, leading to a decrease in numbers of these lymphocytes. 36,37 In this retrospective review of 16 consecutive female patients with vulvar lichen planus, therapy with topical tacrolimus was safe and effective in controlling the symptoms and improving lesions in most (94%) of the patients. Topical tacrolimus is a promising new treatment option for this often recalcitrant and problematic disease. Accepted for publication January 20, Corresponding author and reprints: Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN REFERENCES 1. Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol. 1991;25: Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986;61: Axell T, Rundquist L. Oral lichen planus: a demographic study. Community Dent Oral Epidemiol. 1987;15: Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46: Eisen D. The evaluation of, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88: Pelisse M, Leibowitch M, Sedel D, Hewitt J. A new vulvovaginogingival syn- 719
6 drome: plurimucous erosive lichen planus. Ann Dermatol Venereol. 1982;109: Pelisse M. The vulvo-vaginal-gingival syndrome: a new form of erosive lichen planus. Int J Dermatol. 1989;28: Eisen D. The vulvovaginal-gingival syndrome of lichen planus: the clinical characteristics of 22 patients. Arch Dermatol. 1994;130: Rogers RS III. Erosive orogenital lichen planus in women (vulvovaginal-gingival syndrome) [abstract]. J Oral Pathol Med. 1998;27: Rogers RS III, Eisen D. Erosive oral lichen planus with genital lesions: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin. 2003; 21: Weedon D. The lichenoid reaction pattern. In: Weedon D, ed. Skin Pathology. Edinburgh, Scotland: Churchill Livingstone Inc; 1997: Helander SD, Rogers RS III. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol. 1994;30: Voute AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus: a double-blind, placebocontrolled clinical study. Oral Surg Oral Med Oral Pathol. 1993;75: Boisnic S, Branchet MC, Pascal F, Ben Slama L, Rostin M, Szpirglas H. Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa: a clinical evaluation. Ann Dermatol Venereol. 1994;121: Sieg P, Von Domarus H, Von Zitzewitz V, Iven H, Farber L. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br J Dermatol. 1995; 132: Frances C, Boisnic S, Etienne S, Szpirglas H. Effect of the local application of ciclosporine A on chronic erosive lichen planus of the oral cavity [letter]. Dermatologica. 1988;177: Eisen D, Ellis CN, Duell EA, Griffiths CE, Voorhees JJ. Effect of topical cyclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med. 1990;323: Becherel PA, Chosidow O, Boisnic S, et al. Topical cyclosporine in the treatment of oral and vulvar erosive lichen planus: a blood level monitoring study. Arch Dermatol. 1995;131: Borrego L, Ruiz-Rodriguez R, Ortiz de Frutos J, Vanaclocha Sebastian F, Iglesias Diez L. Vulvar lichen planus treated with topical cyclosporine. Arch Dermatol. 1993;129: Eisen D, Griffiths CE, Ellis CN, Nickoloff BJ, Voorhees JJ. Cyclosporin wash for oral lichen planus. Lancet. 1990;335: Hersle K, Mobacken H, Sloberg K, Thilander H. Severe oral lichen planus: treatment with an aromatic retinoid (etretinate). Br J Dermatol. 1982;106: Sehgal VN, Abraham GJ, Malik GB. Griseofulvin therapy in lichen planus: a doubleblind controlled trial. Br J Dermatol. 1972;87: Massa MC, Rogers RS III. Griseofulvin therapy of lichen planus. Acta Derm Venereol. 1981;61: Eisen D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol. 1993;28: Kumar B, Kaur I, Bhattacharya M. Dapsone in lichen planus [letter]. Acta Derm Venereol. 1994;74: Setterfield JF, Black MM, Challacombe SJ. The management of oral lichen planus. Clin Exp Dermatol. 2000;25: Cribier B, Frances C, Chosidow O. Treatment of lichen planus: an evidencebased medicine analysis of efficacy. Arch Dermatol. 1998;134: Edwards PC, Kelsch R. Oral lichen planus: clinical presentation and management. J Can Dent Assoc. 2002;68: Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol. 1999;140: Lener EV, Brieva J, Schachter M, West LE, West DP, el-azhary RA. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol. 2001; 137: Rozycki TW, Rogers RS III, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol. 2002;46: Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol. 2002;46: Morrison L, Kratochvil FJ III, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol. 2002;47: Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol. 2002;138: Kirtschig G, Van Der Meulen AJ, Ion Lipan JW, Stoof TJ. Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. Br J Dermatol. 2002; 147: Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm. 1995;52: Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135:
SYMPTOMATIC ORAL LICHEN
OBSERVATION Response of Oral Lichen Planus to Topical Tacrolimus in 37 Patients Julie A. Byrd, MD; Mark D. P. Davis, MD; Alison J. Bruce, MD; Lisa A. Drage, MD; Roy S. Rogers III, MD Background: Topical
More informationSTUDY. Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream
STUDY Treatment of Oral Erosive Lichen Planus With Cream A Double-blind, Randomized, Prospective Trial With Measurement of Pimecrolimus Levels in the Blood Thierry Passeron, MD; Jean-Philippe Lacour, MD;
More informationVaginal involvement in genital erosive lichen planus
Acta Obstetricia et Gynecologica. 2010; 89: 966 970 SHORT REPORT Vaginal involvement in genital erosive lichen planus ANNE LISE ORDING HELGESEN 1,2,3, PETTER GJERSVIK 3,4, PETER JEBSEN 5, ROLF KIRSCHNER
More informationSummary. Accepted for publication 18 May Key words genital lichen planus, oral lichen planus, vulval lichen planus
CLINICAL AND LABORATORY INVESTIGATIONS DOI 10.1111/j.1365-2133.2006.07480.x Prevalence of vulval lichen planus in a cohort of women with oral lichen planus: an interdisciplinary study P. Belfiore, O. Di
More informationLichen sclerosus. Lichen planus
Lichen sclerosus Lichen planus Dr Fiona Lewis, Consultant Dermatologist, Heatherwood and Wexham Park NHS Foundation Trust & St John s Institute of Dermatology, GSTT Outline Typical features of lichen sclerosus
More informationNews in erosive lichen planus of the vulva
News in erosive lichen planus of the vulva Anne Lise Helgesen Dermatologist, Postdoc, National Centre of Womens Health, Oslo University Hospital, Oslo, Norway - a great challenge WHY? No evidence based
More informationOriginal Article Oral lichen planus treated with tacrolimus 0.1%
Int J Clin Exp Med 2013;6(10):917-921 www.ijcem.com /ISSN:1940-5901/IJCEM1309016 Original Article Oral lichen planus treated with tacrolimus 0.1% João Paulo Marinho Resende 1, Maria das Graças Afonso Miranda
More informationSTUDY. Influence of Treatment of Erosive Lichen Planus of the Vulva on Its Prognosis
STUDY Influence of Treatment of Erosive Lichen Planus of the Vulva on Its Prognosis Susan M. Cooper, MRCP; Fenella Wojnarowska, DM, FRCP Objective: To record the clinical features, symptomatic response
More informationJMSCR Vol 05 Issue 10 Page October 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i10.125 Histomorphological Study of Lichen Planus
More informationLichen planus. Information for patients Gynaecology
Lichen planus Information for patients Gynaecology page 2 of 8 What is lichen planus? Lichen planus is a non-cancerous, inflammatory skin condition that causes an itchy, non-infectious rash (small purple
More informationPACIFIC JOURNAL OF MEDICAL SCIENCES {Formerly: Medical Sciences Bulletin} ISSN:
PACIFIC JOURNAL OF MEDICAL SCIENCES {Formerly: Medical Sciences Bulletin} ISSN: 2072 1625 Pac. J. Med. Sci. (PJMS) www.pacjmedsci.com. Email: pacjmedsci@gmail.com. EROSIVE LICHEN PLANUS A CASE REPORT *Prathima
More informationDOI /j x
THERAPEUTICS DOI 10.1111/j.1365-2133.2007.08370.x The efficacy of aloe vera gel in the treatment of oral lichen planus: a randomized controlled trial C. Choonhakarn, P. Busaracome, B. Sripanidkulchai*
More informationThe use of CO2 laser for patients with Lichen sclerosus
The use of CO2 laser for patients with Lichen sclerosus Dr. Christina Kuhler-Obbarius, Elisabeth Kunkel, Dr. Matthias Theden-Schow, Hamburg, Germany Our clinical center located in Hamburg includes eight
More informationDisorders of the vulva
Vulval lesions Disorders of the vulva Terminology standardised by the International Society for the Study of Vulvovaginal Disease(ISSVD) Classification 1.Nonneoplastic epithelial disorders of vulva Lichen
More informationConflicts of interest. Genital Lichen Planus. Objectives. Lichen Planus. Genital Lichen Planus. Author Up To Date. Vulvar Lichen Planus Patterns
Genital Lichen Planus Lynette J. Margesson MD FRCPC AAD Washington Mucous Membrane Symposium Saturday, March 2, 2019 Conflicts of interest Author Up To Date Little evidence based treatment Too few studies
More informationConflicts of interest
Vulvar Cases 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology)
More informationOriginal Article. Direct Immunofluorescence in Clinically Diagnosed Oral Lichen Planus
JOMP Journal of Oral Medicine and Pain Original Article pissn 2288-9272 eissn 2383-8493 J Oral Med Pain 2016;41(1):16-20 http://dx.doi.org/10.14476/jomp.2016.41.1.16 Direct Immunofluorescence in Clinically
More informationSCORE 0 SCORE 1 SCORE 2 SCORE 3 Asymptomatic and fully active (ECOG 0; KPS or LPS 100%)
Organ Scoring of Chronic GVHD PERFORMANCE SCORE: KPS ECOG LPS SKIN SCORE % BSA GVHD features to be scored by BSA: applies: Maculopapular rash/erythema Lichen planus-like features Sclerotic features Papulosquamous
More informationClearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera?
DOI: 10.1111/jdv.14516 JEADV SHORT REPORT Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera? A. Borghi,* A. Virgili, S. Minghetti, G. Toni, M. Corazza Dipartimento di Scienze
More informationSuccessful treatment of lichen planus with sulfasalazine in 20 patients
Successful treatment of lichen planus with sulfasalazine in 20 patients A. Bauzá, MD, A. España, MD, P. Gil, MD, P. Lloret, MD, and F. J. Vázquez Doval, MD From the Department of Dermatology, University
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationUnexpectedly High Frequency of Genital Involvement in Women with Clinical and Histological Features of Oral Lichen Planus
Acta Derm Venereol 2006; 86: 433 438 CLINICAL REPORT Unexpectedly High Frequency of Genital Involvement in Women with Clinical and Histological Features of Oral Lichen Planus Olga DI FEDE 1, Pina BELFIORE
More informationTreatment of symptomatic oral lichen planus (OLP) with 0.1% tacrolimus powder in Oraguard-B A pilot prospective study
The Saudi Dental Journal (2012) 24, 143 148 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Treatment of symptomatic oral lichen planus (OLP) with 0.1%
More informationOCCG SERVICE SPECIFICATION (2017/18)
OCCG SERVICE SPECIFICATION (2017/18) Primary Care Service for Skin Cancers: Dermatology Shared Care Monitoring for Melanoma, Lichen Sclerosus and Squamos Cell Carcinoma 1. Background For patients who have
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationTreatment of Bowenoid and Basaloid Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod 5% Cream DO NOT DUPLICATE
The Journal of Reproductive Medicine Treatment of Bowenoid and Basaloid Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod 5% Cream Claudia Marchitelli, M.D., Graciela Secco, M.D., Myriam Perrotta, M.D.,
More informationAmerican Journal of Cancer Science
American Journal of Cancer Science http://ivyunion.org/index.php/ajcs/ Akerzoul N et al. American Journals of Cancer Science 2015, 5:63-77 Page 1 of 6 Case Report Malignant Transformation of Erosive Oral
More informationImmunoflourescent assessment of Herpes Simplex Virus (HSV) type 1 in oral lichen planus
Immunoflourescent assessment of Herpes Simplex Virus (HSV) type 1 in oral lichen planus Muthanna K. Ali, B.D.S., M.Sc. (1) ABSTRACT Background: Oral lichen planus is one of the most common dermatological
More informationCancer risk of Lichen planus. Halonen, Pia
https://helda.helsinki.fi Cancer risk of Lichen planus Halonen, Pia 2018-01-01 Halonen, P, Jakobsson, M, Heikinheimo, O, Riska, A, Gissler, M & Pukkala, E 2018, ' Cancer risk of Lichen planus : A cohort
More informationDesquamative inflammatory vaginitis. A review
Genitourin Med 1990;66:275-279 Desquamative inflammatory vaginitis. A review J K Oates, D Rowen Abstract Desquamative inflammatory vaginitis is an uncommon cause of an intractable vaginitis often accompanied
More information4/3/2017 DIAGNOSIS AND THERAPY OF RECURRENT VULVOVAGINAL SYMPTOMS BACTERIAL VAGINOSIS EPIDEMIOLOGY OBJECTIVES
DIAGNOSIS AND THERAPY OF RECURRENT VULVOVAGINAL SYMPTOMS KELLY HODGES, MD (NO DISCLOSURES) OBJECTIVES REVIEW THE TWO MOST COMMON CAUSES OF RECURRENT ABNORMAL DISCHARGE (CANDIDA AND BV) REVIEW THE MOST
More informationAutoimmune Diseases with Oral Manifestations
Autoimmune Diseases with Oral Manifestations Martin S. Greenberg DDS, FDS RCSEd Professor Emeritus Department of Oral Medicine University of Pennsylvania Disclosure Statement I have no actual or potential
More informationSuccessful treatment of Oral Lichen Planus (OLP) with 0.1% topical Tacrolimus in a patient with impaired liver enzymes: A Case report
American Journal of Advances in Medical Science www.arnaca.com Vol-2: No-1: 7-11:2014 Case Report Successful treatment of Oral Lichen Planus (OLP) with 0.1% topical Tacrolimus in a patient with impaired
More informationCases of Non-Infectious Vulvovaginitis
Cases of Non-Infectious Vulvovaginitis 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology
More informationSetting The setting was tertiary care. The economic study was carried out in Turin, Italy.
Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R,
More informationWELCOME. Training village
WELCOME Training village PERFORM EASY AND PAINLESS VAGINAL DRYNESS TREATMENT WITH ELEA Dr Bertrand Durantet Aesthetic Doctor LYON France PART 1 FEATURES ON ELEA THE MAGNETIC SUPPORT THE FOOT PEDAL THE
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 31 January 2007 BUCCOBET 0.1 mg, oromucosal tablet B/50 (CIP: 3741470 ) Applicant: DB PHARMA Betamethasone valerate
More informationPatient Satisfaction of Surgical Treatment of Clitoral Phimosis and Labial Adhesions Caused by Lichen Sclerosus
ORIGINAL RESEARCH WOMEN S SEXUAL HEALTH Patient Satisfaction of Surgical Treatment of Clitoral Phimosis and Labial Adhesions Caused by Lichen Sclerosus Anne N. Flynn, MD,* Michelle King, MSc, Mollie Rieff,
More informationDOI /j x
THERAPEUTICS DOI 10.1111/j.1365-2133.2007.07883.x Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial G. Lodi, M. Tarozzi, A. Sardella, F. Demarosi, L. Canegallo,
More informationINFLAMMATORY DISEASES PART I. Immunopathology Part I
INFLAMMATORY DISEASES PART I Immunopathology Part I Nonspecific & T Cell Mediated Mucosal Inflammatory Lesions Nonspecific and Idiopathic Mucositis Hypersensitivity and Autoimmune T cell mediated Immunoglobulin
More informationDiagnosis and Management of Vulvar Disorders
Diagnosis and Management of Vulvar Disorders Kelly H. Tyler, MD, FACOG, FAAD Assistant Professor The Ohio State University Department of Internal Medicine, Division of Dermatology Department of Obstetrics
More informationVulvo-vaginal chronic Graft-versus-Host Disease
Vulvo-vaginal chronic Graft-versus-Host Disease Eva Smith Knutsson Senior doctor, clinical sexologist, Dpt of Obstetrics and Gynecology, NU Hospital Group,Trollhättan PhD student, Sahlgrenska Academy,
More informationChildhood Oral Lichen Planus: Report of Two Cases
Case Report Sageena George 1, Sheen Ann John 2, Anandaraj S 3, Jyoti Sumi Issac 4, Anoop Harris 5, Reshmi J 6 1 Professor, Department of Pedodontics and Preventive Dentistry, PMS College of Dental Science
More informationA Clinical Study of Oral Mucous Membrane Pemphigoid
The Journal of International Medical Research 2003; 31: 340 344 A Clinical Study of Oral Mucous Membrane Pemphigoid A ALKAN 1, Ö GÜNHAN 3, A ALKAN 2 AND F OTAN 2 1 Department of Oral and Maxillofacial
More informationOral Manifestations of Dermatologic Disease: A Focus on Lichenoid Lesions. Proceedings of the NASHNP Companion Meeting, March, 2011, San Antonio, TX
1 Oral Manifestations of Dermatologic Disease: A Focus on Lichenoid Lesions Proceedings of the NASHNP Companion Meeting, March, 2011, San Antonio, TX Susan Müller, DMD, MS Professor Department of Pathology
More informationClassification: 1. Infective: 2. Traumatic: 3. Idiopathic: Recurrent Aphthous Stomatitis (RAS) 4. Associated with systemic disease:
Classification: 1. Infective: 2. Traumatic: 3. Idiopathic: Recurrent Aphthous Stomatitis (RAS) 4. Associated with systemic disease: Hematological GIT Behcet s HIV 5. Associated with dermatological diseases:
More informationInflammatory Dermatoses of the Vulva for the General/Gyn Pathologist with emphasis in the lichenoid pattern
Inflammatory Dermatoses of the Vulva for the General/Gyn Pathologist with emphasis in the lichenoid pattern By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor
More informationBMT CTN 0801 Protocol. Chronic GVHD Provider Survey. FOLLOW-UP v3.0
BMT CTN 0801 Protocol Chronic GVHD Provider Survey FOLLOW-UP v3.0 Instructions: Please score a symptom only if you know or suspect it be related to chronic GVHD. Subjective are acceptable. For example,
More informationAllergic contact stomatitis is a rare disorder,
Allergic Contact Stomatitis: A Case Report and Review of Literature P Lokesh, T Rooban, Joshua Elizabeth, K Umadevi, K Ranganathan Abstract Allergic contact stomatitis is a well-recognized entity, which
More informationAsymptomatic Undiagnosed Lichen Sclerosus
Asymptomatic Undiagnosed Lichen Sclerosus Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology) Geisel School of Medicine at Dartmouth Lebanon, NH, USA Disclosures
More informationLichen sclerosus (LS) is an uncommon inflammatory. Constipation as a Feature of Anogenital Lichen Sclerosus in Children
Mandi L. Maronn, MD*, and Nancy B. Esterly, MD ABSTRACT. Objective. To call attention to constipation as a frequent sign of lichen sclerosus (LS) in girls. Methods. A focused questionnaire was sent to
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2016, Vol. 2, Issue 5, 183-198. Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 3.347 EVALUATION OF EFFICACY OF TACROLIMUS AND TRIAMCINOLONE ACETONIDE OINTMENT IN THE MANAGEMENT
More informationA New Approach to the Pharmacological Treatment. of Oral Lichen Planus: Case Report
Case Report 57 Copyright University of Medicine, Tirana AJMHS Vol. 47 (2/3): 57-65 2016 A New Approach to the Pharmacological Treatment of Oral Lichen Planus: Case Report Besian Abazi 1, Joana Mihani 2
More informationDiseases of the vulva
Diseases of the vulva 1. Bartholin Cyst - Infection of the Bartholin gland produces an acute inflammation within the gland (adenitis) and may result in an abscess. Bartholin duct cysts - Are relatively
More information2018 Oregon Dental Conference Course Handout Denis Lynch, DDS, PhD
2018 Oregon Dental Conference Course Handout Denis Lynch, DDS, PhD Course 9148: Diagnosis and Treatment of Recurrent Oral Ulcers Friday, April 6 9 am - 12 pm Diagnosis and Treatment of Recurrent Oral Ulcers
More informationSmoking Habits Among Patients Diagnosed with Oral Lichen Planus
TOBACCO INDUCED DISEASES Vol. 2, No. 2: 103-108 (2004) PTID Society Smoking Habits Among Patients Diagnosed with Oral Lichen Planus Meir Gorsky, 1 Joel B. Epstein, 2 Haya Hasson-Kanfi, 1 Eliezer Kaufman
More information** IMPORTANT!! PLEASE READ THIS BEFORE YOU FILL OUT YOUR QUESTIONNAIRE! **
** IMPORTANT!! PLEASE READ THIS BEFORE YOU FILL OUT YOUR QUESTIONNAIRE! ** WHY AM I FILLING OUT THIS FORM? Your responses will help us to understand your experience. Please take your time and try to answer
More informationAnne Arundel Medical Center Informed Consent
Informed Consent Title: Exploratory Trial of Autologous Platelet Rich Plasma (PRP) Intradermal Injections for the Treatment of Vulvar Lichen Sclerosus Investigator: Andrew Goldstein, M.D. Telephone Study
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationEXTERNAL ANOGENITAL WARTS
EXTERNAL ANOGENITAL WARTS Whats new HPV vaccination is now available to MSM under the age of 45 years attending Sexual Health Services. This vaccination is recommended even if a prior/current history of
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationLichen sclerosus. Information for patients Gynaecology
Lichen sclerosus Information for patients Gynaecology page 2 of 8 What is lichen sclerosus? Lichen sclerosus is a skin condition that most often affects the vulva (the outer folds of skin around your vagina).
More informationAcitretin for Severe Lichen Sclerosus of Male Genitalia: A Randomized, Placebo Controlled Study
Acitretin for Severe Lichen Sclerosus of Male Genitalia: A Randomized, Placebo Controlled Study D. Ioannides, E. Lazaridou,* Z. Apalla, E. Sotiriou, S. Gregoriou and D. Rigopoulos From the First Department
More informationManagement of Pyoderma Gangrenosum Mentoring in IBD XVII
Management of Pyoderma Gangrenosum Mentoring in IBD XVII Scott Walsh MD PhD FRCPC Division of Dermatology Sunnybrook Health Sciences Centre University of Toronto Pyoderma Gangrenosum: A pathological
More informationS003 CPC Self-Assessment
S003 CPC Self-Assessment Alina G. Bridges, D.O. Associate Professor Program Director, Dermatopathology Fellowship Department of Dermatology, Division of Dermatopathology and Cutaneous Immunopathology Mayo
More informationIntroduction to Pemphigoid: Spectrum of Disease & Treatment
Introduction to Pemphigoid: Spectrum of Disease & Treatment A Razzaque Ahmed, MD Center for Blistering Diseases Boston, MA A.Razzaque.Ahmed@tufts.edu centerforblisteringdiseases.com SPECTRUM OF PEMPHIGOID
More informationTreatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution
Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution Miguel Angel Gonzalez-Moles, MD, PhD, a Patricia Morales, DDS, PhD, b Alberto Rodriguez- Archilla, DDS, PhD,
More informationComparison of Two Corticosteroids Mouthwashes in Treatment of Symptomatic Oral Lichen Planus
Ahadian H., et al J Dent Shiraz Univ Med Scien. 212 June; 13(2): 49-53 Original Article Comparison of Two Corticosteroids Mouthwashes in Treatment of Symptomatic Oral Lichen Planus Ahadian H. a, Akhavan
More informationRole of direct immunofluorescence on Tzanck smear and plucked hair in the diagnosis of pemphigus vulgaris
Original Article Role of direct immunofluorescence on Tzanck smear and plucked hair in the diagnosis of pemphigus vulgaris Kehkshan Tahir, Saelah Batool, Muhammad Shahid, Shahbaz Aman Department of Dermatology,
More informationLichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience
Original article CED Clinical and Experimental Dermatology Lichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience F. Mardones 1 and J. Shapiro
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationIncrease in common cold symptoms and mouth ulcers following
Increase in common cold symptoms and mouth ulcers following smoking cessation Michael Ussher*, Robert West *, Andrew Steptoe **, Andy McEwen* *Department of Psychology, Hunter Wing, St. George's Hospital
More informationBMT CTN 0801 Protocol. Chronic GVHD Provider Survey ENROLLMENT
BMT CTN 0801 Protocol Chronic GVHD Provider Survey ENROLLMENT Instructions: Please score a symptom only if you know or suspect it be related to chronic GVHD. Subjective are acceptable. For example, joint
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationDisclosures Dr. Lynette Margesson
Management of Vulvar Pruritus 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and
More informationWhat you need to know about EGW
For the treatment of external genital and perianal warts (EGW) What you need to know about EGW Indication VEREGEN is indicated for the topical treatment of external genital and perianal warts (Condylomata
More informationSHORT REPORT FRONTAL FIBROSING ALOPECIA IN A PREMENOPAUSAL WOMAN: IMMUNOHISTOCHEMICAL AND IMMUNOFLUORESCENCE ANALYSIS
EUROPEAN JOURNAL OF INFLAMMATION Vol. 5, no. 1, 23-27 (2007) SHORT REPORT FRONTAL FIBROSING ALOPECIA IN A PREMENOPAUSAL WOMAN: IMMUNOHISTOCHEMICAL AND IMMUNOFLUORESCENCE ANALYSIS G.I. ATHANASIADIS, E.
More informationVIN/VAIN O C T O B E R 3 RD J M O R G A N
VIN/VAIN O C T O B E R 3 RD 2 0 1 8 J M O R G A N Vaginal Intraepithelial Neoplasia VAIN I, II, III Incidence 0.1/100,000 women in US Mean age 50s (J Womens Health (Larchmt) 2009:18:1731) (J Obstet Gynaecol
More informationLESIONS OF THE ORAL CAVITY ORAL CAVITY. Oral Cavity Subsites 4/10/2013 LIPS TEETH GINGIVA ORAL MUCOUS MEMBRANES PALATE TONGUE ORAL LYMPHOID TISSUES
LESIONS OF THE ORAL CAVITY David I. Kutler, MD, FACS Associate Professor Division of Head and Neck Surgery Department of Otolaryngology HNS Weill Cornell Medical Center ORAL CAVITY LIPS TEETH GINGIVA ORAL
More informationDr. Saeed A-Latteef A- kareem 1, Dr. Khadija M Ahmed 1
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 10 Ver. V (Oct. 2015), PP 80-84 www.iosrjournals.org Prevalence of Aphthous Ulceration in patients
More informationInteresting Case Series. Linear IgA Bullous Dermatosis
Interesting Case Series Linear IgA Bullous Dermatosis Sean Chen, BA, a Peter Mattei, MD, a Max Fischer, MD, MPH, a Joshua D. Gay, PA-C, b Stephen M. Milner, MBBS, BDS, FRCS (Ed), FACS, b and Leigh Ann
More informationInformed Consent And Authorization To Disclose Health Information
Gynecologic Cancer Research Foundation Page 1 of 11 Informed Consent And Authorization To Disclose Health Information Sponsor / Study Title: Principal Investigator: (Study Doctor) Gynecologic Cancer Research
More informationBenign Oral cavity lesions. Mohammed ALESSA MBBS,FRCSC Assistant Professor Consultant Otolaryngology, Head & Neck Surgery
Benign Oral cavity lesions Mohammed ALESSA MBBS,FRCSC Assistant Professor Consultant Otolaryngology, Head & Neck Surgery Anatomy Histology Physiology Pathology Clinical cases Introduction The oral cavity
More informationPrepubertal labial adhesions: Evaluation of a referral population
Prepubertal labial adhesions: Evaluation of a referral population Janice L. Bacon, MD Columbia, SC OBJECTIVE: The purpose of this study was to assess patient demographics, clinical presentation, response
More informationKelly H. Tyler, MD, FACOG, FAAD S052 Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders Vulvar Dermatitis
Vulvar Dermatitis Kelly H. Tyler, MD, FACOG, FAAD Assistant Professor The Ohio State University Department of Internal Medicine, Division of Dermatology Department of Obstetrics and Gynecology Center for
More informationOral & Vulvovaginal GVHD. Rachel Kornik, MD Assistant Professor of Dermatology University of Wisconsin Hospital and Clinics
Oral & Vulvovaginal GVHD Rachel Kornik, MD Assistant Professor of Dermatology University of Wisconsin Hospital and Clinics DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Rachel Kornik, MD S001 Advanced Medical
More informationEFFICACY AND SAFETY OF CLOBETASOL PROPIONATE SHAMPOO IN THERAPY OF PSORIASIS OF THE SCALP
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Platonova et al. SJIF Impact Factor 2.786 Volume 4, Issue 04, 238-246. Research Article ISSN 2278 4357 EFFICACY AND SAFETY OF CLOBETASOL PROPIONATE
More informationProliferative Verrucous Leukoplakia of the Gingiva, Report of two Cases with Malignant Transformation
Journal of Clinical and Anatomic Pathology Case Report Open Access Proliferative Verrucous Leukoplakia of the Gingiva, Report of two Cases with Malignant Transformation Nadereh Ghanee DMD, Selene Saraf
More informationThe Case of Mrs. Virginia Jones* Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver, Canada
Case title: Case authors: Case synopsis: The Case of Mrs. Virginia Jones* Dr. Leslie A. Sadownik Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver,
More informationWOMEN'S INTERAGENCY HIV STUDY GYNECOLOGICAL EXAM FORM 8
WOMEN'S INTERAGENCY HIV STUDY GYNECOLOGICAL EXAM FORM 8 AFFIX ID LABEL HERE ---> PARTICIPANT ID: (Enter number here only if ID label is not available) - - - WIHS STUDY VISIT #: FORM VERSION: 04/01/99 EXAMINER'S
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To assure that DOP inmates with skin lesions are receiving appropriate Primary Care for their lesions POLICY All DOP Primary Care Providers are expected to follow this guideline and/or
More informationWHITE PAPER SmartXide 2 V 2 LR. MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy
WHITE PAPER SmartXide 2 V 2 LR MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy DEKA White Paper SMARTXIDE 2 V 2 LR November 2015 MonaLisa Touch Dual Probe Therapy
More informationOBSERVATION. Decreased Skin Cancer After Cessation of Therapy With Transplant-Associated Immunosuppressants
OBSERVATION Decreased Skin Cancer After Cessation of Therapy With Transplant-Associated Immunosuppressants Clark C. Otley, MD; Brett M. Coldiron, MD; Thomas Stasko, MD; Glenn D. Goldman, MD Background:
More informationBritish Association of Dermatologists guidelines for the management of lichen sclerosus 2018
British Association of Dermatologists guidelines for the management of lichen sclerosus 2018 WEB APPENDIX SUPPLEMENTARY INFORMATION Appendix A: Review Protocol Appendix B: Clinical Evidence summary Appendix
More informationCHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)
CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation) Participant Initials: Date of Birth: Were the following forms completed for this visit? Follow Up Form Done t Done BVASWG
More informationOral toxicitiesof immune checkpoint inhibitors
Oral toxicitiesof immune checkpoint inhibitors Emmanuelle Vigarios (1) Vincent Sibaud (1,2) (1) Oral medicinedepartment (2) Onco-dermatology and clinical research departments Institut Claudius Regaud,
More informationGraft-versus-Host Disease of the Vulva and/or Vagina: Diagnosis and Treatment
Biology of Blood and Marrow Transplantation 9:760-765 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0912-0004$30.00/0 doi:10.1016/j.bbmt.2003.08.001 Graft-versus-Host Disease
More informationIt has been estimated that 90% of individuals
Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1
More information